Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) is now available.
ASKA Pharmaceutical Holdings Co., Ltd. reported record-high sales in the third quarter of FY2024, driven by continued growth in its pharmaceutical and animal health businesses. Despite increased sales, operating profit remained stable year-over-year due to rising SG&A expenses linked to R&D progress, while the cost of sales ratio improved due to a favorable product mix.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceuticals and animal health products. The company is known for brand-name drugs such as RELUMINA and RIFXIMA.
YTD Price Performance: -6.29%
Average Trading Volume: 58,094
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen55.89B
See more data about 4886 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue